Background: The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the...
L’intérêt pour la psilocybine, une substance présente dans les champignons dits « magiques », connaît un regain marqué en psychiatrie et en soins palliatifs. Bien étudiée dans les années 1950 et 1960, elle est tombée dans l’oubli avec l’interdiction des drogues et le déclin de la contre-culture dans les années 1970. Aujourd’hui, son retour soulève des questions sur son potentiel en soins...
Psychedelics are psychoactive substances that cause changes in perception, state of consciousness, mood and numerous cognitive processes. The best known are lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), psilocybin and mescaline. The main mechanism of action of psychedelics is agonism towards serotonin 5-HT2A receptors. In the middle of the 20th century, interest in the use of...
Existential and spiritual suffering are frequently reported by individuals facing serious illnesses, particularly at the end of life, and are associated with diminished quality of life, increased psychological distress, and requests for hastened death. While Palliative Care (PC) aims to provide holistic support, existing therapeutic options often fail to adequately address the profound...
Classic psychedelics such as LSD, psilocybin, and DMT from unregulated markets pose considerable risks through unknown adulterants and potencies. In this chapter, we explore the importance of drug checking in minimizing harm among users of classic psychedelics and examine the opportunities and challenges associated with intervention settings, analytical techniques, and risk communication...
Psilocybin is an alkaloid known for its psychedelic effects by activating serotonin receptors and there is growing interest in using psilocybin to treat mental disorders such as depression and anxiety, which are not fully understood and difficult to treat with conventional medications. This research aims to review the evidence from preclinical and clinical studies on the use of psilocybin for...
NeuroImage: Clinical2025Gianna M. Perez, Benjamin M. Rosenberg, Wenyi Xu et al.3 citations
BACKGROUND: Understanding changes in brain activity following treatment is critical to advancing the use of neuroimaging in psychiatric research. Previous work has focused on defining abnormalities (biomarkers) between patients and healthy controls but there has been less investigation of brain changes in depression patients following treatment. To boost sample size and explore the possibility...
OBJECTIVE: Despite growing research on the potential mental health benefits of psychedelics, there has been limited study of these drugs in populations with obsessive-compulsive disorder (OCD) and with Hispanic and Latin American (H/L) ancestry. METHODS: Demographic and clinical assessments were conducted as part of the Latin American Trans-ancestry Initiative for OCD genomics (LATINO) Study in...
Mental health disorders such as depression are a rising issue among university students. Some of them use complementary and alternative medicine (CAM) as self-administered therapy instead of or together with professional care. Defining the scale of the problem, its underlying reasons and possible implications are crucial for addressing it in clinical psychiatry and public health strategies. A...
Psychedelic compounds, including psilocybin, psilocin, lysergic acid diethylamide (LSD), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), and mescaline, have long been recognized for their recreational effects and involvement in forensic cases. They have recently gained attention also for their potential therapeutic applications in treating neurological and psychiatric disorders [1]. Despite this...